IP Library › Granted Patent US 10,442,864
Granted Patent B2
US 10,442,864 · App. 16/007,399 · Granted Oct 15, 2019

Anti-Tie2 antibodies and uses thereof

Inventor: Gavin Thurston (Briarcliff Manor, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
C07K16/2863A61K39/3955A61K39/39533C07K16/40A61K39/395A61K2039/505C07K14/705C07K14/71C07K16/28C07K16/2896C07K2317/21C07K2317/33C07K2317/34C07K2317/56C07K2317/565C07K2317/76C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,442,864
App. No.
16/007,399
Granted
Oct 15, 2019
Kind
B2
Abstract

The present invention provides antibodies that bind to Tie2 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Tie2 and block the interaction between Tie2 and one or more Tie2 ligands such as angiopoietin 1 (Ang1), angiopoietin 2 (Ang2), angiopoietin 3 (Ang3) and/or angiopoietin 4 (Ang4). The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Tie2 biological activities including angiogenesis.

Claims (7)

1. An isolated antibody or antigen-binding fragment thereof that specifically binds human Tie2, comprising the complementarity determining regions (CDRs), HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, of an antibody produced from a cell line deposited with the American Type Culture Collection under accession number PTA-12296.

2. The isolated antibody or antigen-binding fragment of claim 1 , comprising the variable regions of an antibody produced from a cell line deposited with the American Type Culture Collection under accession number PTA-12296.

3. The isolated antibody or antigen-binding fragment of claim 1 that is an antibody.

4. The isolated antibody of claim 3 that is an IgG1 antibody.

5. The isolated antibody of claim 3 that is an IgG4 antibody.

6. The isolated antibody or antigen-binding fragment of claim 1 that is an antigen-binding fragment.

7. The isolated antibody or antigen-binding fragment of claim 1 that is multispecific.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2018
From: THURSTON, GAVIN
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 046357/0882 →
Continuity (7)
Continuation 15373903 · Dec 9, 2016
Continuation 14671494 · Mar 27, 2015
Division 13586911 · Aug 16, 2012
Provisional Application 61674405 · Jul 23, 2012
Provisional Application 61587213 · Jan 17, 2012
Provisional Application 61525308 · Aug 19, 2011
Related Publication 20180291105A1 · Oct 11, 2018